Microbot Medical’s (MBOT) Buy Rating Reiterated at B. Riley Financial

Microbot Medical (NASDAQ:MBOT)‘s stock had its “buy” rating reaffirmed by research analysts at B. Riley Financial in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $4.00 price objective on the biotechnology company’s stock, down from their previous price objective of $5.00. B. Riley Financial’s price target would indicate a potential upside of 146.31% from the stock’s previous close.

A number of other equities research analysts have also commented on MBOT. HC Wainwright reissued a “buy” rating on shares of Microbot Medical in a report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th. Zacks Research raised shares of Microbot Medical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 22nd. Loop Capital set a $4.00 price target on shares of Microbot Medical in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Microbot Medical presently has an average rating of “Moderate Buy” and an average price target of $6.38.

Microbot Medical Price Performance

Microbot Medical stock traded down $0.06 on Friday, reaching $1.62. The company’s stock had a trading volume of 668,963 shares, compared to its average volume of 1,516,209. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The company has a market cap of $109.08 million, a price-to-earnings ratio of -6.75 and a beta of 1.06. The business’s fifty day moving average price is $1.82 and its 200 day moving average price is $2.06. Microbot Medical has a twelve month low of $1.60 and a twelve month high of $4.67.

Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.20 million. Equities analysts expect that Microbot Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. bought a new position in shares of Microbot Medical in the 1st quarter valued at about $28,000. American Century Companies Inc. bought a new stake in shares of Microbot Medical during the second quarter worth approximately $32,000. Zacks Investment Management acquired a new position in Microbot Medical in the third quarter valued at approximately $33,000. Man Group plc bought a new position in Microbot Medical in the fourth quarter valued at approximately $35,000. Finally, Squarepoint Ops LLC bought a new position in Microbot Medical in the third quarter valued at approximately $37,000. Institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.